CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $260.17M, lower than 95% of all stocks globally
- PositionGross margin is -102.5%, lower than 95% of its Biotechnology peers (median 67.2%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.24BTWD260.17M · vs all stocks (USD)
Revenue (TTM)
657.56MTWD20.76M · vs all stocks (USD)
Profit Margin
-222.84%vs Biotechnology peers
Beta
0.2030xvs all stocks
52-Week Change
-36.27%vs all stocks
Market Capitalization
8.24BTWD260.17M · vs all stocks (USD)
Enterprise Value
10.10BTWD318.95M · vs all stocks (USD)
Forward P/E
-8.38xvs Biotechnology peers
Price to Sales (TTM)
12.63xvs Biotechnology peers
Price to Book (MRQ)
1.67xvs Biotechnology peers
Enterprise to Revenue
15.37xvs Biotechnology peers
Enterprise to EBITDA
-7.78xvs Biotechnology peers
Gross Margin
-102.49%vs Biotechnology peers
Profit Margin
-222.84%vs Biotechnology peers
Operating Margin
-166.52%vs Biotechnology peers
Return on Assets (TTM)
-12.28%vs Biotechnology peers
Return on Equity (TTM)
-29.78%vs Biotechnology peers
Revenue (TTM)
657.56MTWD20.76M · vs all stocks (USD)
Revenue per Share (TTM)
2.51TWDUpdated Sep 22, 2026Quarterly Revenue Growth
370.80%vs Biotechnology peers
Gross Profit (TTM)
-898.48MTWD-28.36M · vs all stocks (USD)
EBITDA (TTM)
-1.30BTWD-40.98M · vs all stocks (USD)
Net Income (TTM)
-1.47BTWD-46.26M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
370.84%vs Biotechnology peers
Operating Cash Flow (TTM)
-934.96MTWD-29.52M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.27BTWD-39.98M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
400.97MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
841.68MTWDFY2025 · Dec 31, 2025Gross Profit
-440.71MTWDFY2025 · Dec 31, 2025Operating Income
-1.38BTWD-43.62M · vs all stocks (USD)
Pre-tax Income
-1.50BTWDFY2025 · Dec 31, 2025Income Tax Expense
-3.05MTWDFY2025 · Dec 31, 2025Net Income
-1.50BTWDFY2025 · Dec 31, 2025EBIT
-1.46BTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-1.08BTWDFY2025 · Dec 31, 2025Research & Development
510.82MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
430.19MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
39.88MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
47.23MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-1.56BTWDFY2025 · Dec 31, 2025Free Cash Flow
-2.21BTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
878.71MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.50BTWDFY2025 · Dec 31, 2025Stock-based Compensation
9.07MTWDFY2025 · Dec 31, 2025Other Non-cash Items
8.27MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
161.97MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-231.76MTWDFY2025 · Dec 31, 2025Capital Expenditures
-655.35MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.94MTWDFY2025 · Dec 31, 2025Net Acquisitions
1.00BTWDFY2025 · Dec 31, 2025Purchase of Investments
-300.00KTWDFY2025 · Dec 31, 2025Sale of Investments
5.30MTWDFY2025 · Dec 31, 2025Other Investing Activity
-50.16MTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
303.75MTWDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00TWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
30.00MTWDFY2025 · Dec 31, 2025Other Financing Charges
222.00KTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
1.29BTWDFY2025 · Dec 31, 2025Shares Outstanding
264.99MSharesUpdated Sep 22, 2026Float Shares
108.19MSharesUpdated Sep 22, 2026% Held by Insiders
65.14%vs all stocks
% Held by Institutions
0.08%vs all stocks
Total Cash (MRQ)
592.56MTWD18.71M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.24TWDUpdated Sep 22, 2026Total Debt (MRQ)
2.08BTWD65.77M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4196xvs Biotechnology peers
Current Ratio (MRQ)
1.47xvs Biotechnology peers
Book Value per Share (MRQ)
18.74TWDUpdated Sep 22, 2026Total Assets
7.96BTWD251.33M · vs all stocks (USD)
Total Current Assets
1.50BTWDFY2025 · Dec 31, 2025Total Liabilities
2.27BTWDFY2025 · Dec 31, 2025Total Non-current Assets
6.46BTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.47BTWDFY2025 · Dec 31, 2025Total Current Liabilities
799.66MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
878.71MTWDFY2025 · Dec 31, 2025Accounts Receivable
30.20MTWDFY2025 · Dec 31, 2025Inventory
416.48MTWDFY2025 · Dec 31, 2025Accounts Payable
102.98MTWDFY2025 · Dec 31, 2025Short-term Debt
211.63MTWDFY2025 · Dec 31, 2025Other Current Liabilities
819.00KTWDFY2025 · Dec 31, 2025Long-term Debt
1.37BTWDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.72MTWDFY2025 · Dec 31, 2025Common Stock (Book)
2.65BTWDFY2025 · Dec 31, 2025Retained Earnings
-15.64BTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
5.69BTWD179.75M · vs all stocks (USD)
52-Week Low
30.30TWDUpdated Sep 22, 202652-Week High
68.00TWDUpdated Sep 22, 202652-Week Change
-36.27%vs all stocks
Beta
0.2030xvs all stocks
50-Day MA
36.15TWDUpdated Sep 22, 2026200-Day MA
43.39TWDUpdated Sep 22, 2026Avg 10-Day Volume
372.01KSharesUpdated Sep 22, 2026Avg 30-Day Volume
374.05KSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-5.54TWDUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -102.5%, lower than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: -1.02Industry median: 0.67Industry P5: 0.14Peers compared: 260
Financial Health
Altman Z-Score -1.02: distress zoneCritical
Altman Z-Score: -1.02
High structural barrier to entryNotable
Barrier to Entry: 172.477
Consistent revenue growth patternNotable
Growth Consistency Score: 0.94
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $260.17M, lower than 95% of all stocks globallySignificant
Market cap (USD): 260,169,401.226Global P5: 275,556,405.438
Revenue is $20.76M, lower than 95% of all stocks globallySignificant
Revenue (USD): 20,758,511.64Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Lineage Cell Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule